Efficacy and toxicity profiles of two chemoradiotherapies for stage II laryngeal cancer – a comparison between late course accelerated hyperfractionation (LCAHF) and conventional fractionation (CF)

Abstract

Objective: To evaluate the treatment results of late course accelerated hyperfractionation (LCAHF) compared with conventional fractionation (CF) for stage II laryngeal cancer.

Methods: Fifty-nine consecutive patients treated for stage II laryngeal cancer were retrospectively reviewed. Thirty-two patients underwent LCAHF, twice-daily fractions during the latter half with a total dose of 69 Gy. Twenty-seven patients received CF of 70 Gy.

Results: The local control rates (LCRs), overall survival (OS), and disease-specific survival (DSS) at 5 years were 80.6%, 74.0%, and 90.4%, respectively, after LCAHF and 64.7%, 68.2%, and 90.5%, respectively, after CF. There were no significant differences in LCR, OS, and DSS (p = .11, 0.68, and 0.69, respectively). In a small number of patients with supraglottic cancer, LCAHF was associated with a significantly higher LCR at 5 years compared with CF (100% vs. 41.7%; p = .02).

Conclusions: This is the first report that compared the results of LCAHF and CF for stage II laryngeal cancer. We could not find significant differences in LCR, DSS, and OS rates between LCAHF and CF groups. Although in a small number of patients with supraglottic cancer, LCAHF may improve the LCR compared with CF.

Chinese abstract

结论：这是关于比较对II期喉癌进行的晚期加速超分割（LCAHF）和常规分级（CF）的结果的第一份报告。我们没有发现LCAHF组和CF组之间的LCR, DSS和OS率有显著差异。虽然在少数有声门癌的患者中, 相较于CF, LCAHF可能改善LCR。

目的：评价晚期加速超分割对II期喉癌的治疗结果, 并与常规分级相比。

方法：回顾性审查了59例连续II期喉癌患者。 32例患者接受LCAHF, 在后半期每日两次, 总剂量为69 Gy。二十七名患者接受剂量为70 Gy的CF。

结果：进行LCAHF治疗后, 5年时的局部控制率（LCR）、总生存率（OS）和特定疾病生存率（DSS）分别为80.6%、74.0%和90.4%；进行CF治疗后, 这些比率分别为64.7%, 68.2% 90.5%。 LCR、OS和DSS没有显著差异（分别为p = 0.11、0.68和0.69）。在少数患有声门下癌的患者中, LCAHF与CF相比在5年时具有显著较高的LCR（100%对41.7%; p = 0.02）。

Keywords:

• Late course accelerated hyperfractionation
• accelerated hyperfractionation
• concurrent chemoradiotherapy
• laryngeal cancer

Disclosure statement

The authors declare that they have no conflict of interest directly relevant to the content of this article.